CFHR2: A Potential Drug Target and Biomarker (G3080)

Target Name: CFHR2

NCBI ID: G3080

CFHR2

CFHR2: A Potential Drug Target and Biomarker

Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide, placing a significant burden on society. The failure of the cardiovascular system to function properly due to the buildup of plaque in the arteries can lead to heart attacks, strokes, and other complications. The discovery of potential drug targets and biomarkers for CVD could lead to new treatments and improve patient outcomes. One such potential drug target and biomarker is CFHR2, which has been identified as a potential drug target in the field of CVD.

CFHR2 stands for Familial Hypercholesterolemia Registry 2, a gene that encodes a protein known as CFHR2. Hypercholesterolemia, or high cholesterol levels, is a condition that can lead to the development of heart disease and stroke. The CFHR2 gene has been shown to play a significant role in the regulation of cholesterol levels and the development of hypercholesterolemia.

Studies have shown that individuals with Familial Hypercholesterolemia (FH) are at a higher risk for developing cardiovascular disease than those without the condition. FH is a genetic disorder that is characterized by the accumulation of high levels of cholesterol in the blood. Individuals with FH may experience symptoms such as chest pain, shortness of breath, and fatigue due to the buildup of plaque in the arteries.

CFHR2 has been shown to be a key regulator of cholesterol levels and has been linked to the development of FH. Studies have shown that individuals with FH have lower levels of CFHR2 than those without the condition. Additionally, individuals with FH have higher levels of certain biomarkers that are associated with the development of heart disease, such as C-reactive protein (CRP) and BNP.

CFHR2 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. Angiogenesis is a critical process for the development and maintenance of the blood supply to the body. Studies have shown that individuals with FH have lower levels of CFHR2 in the vessels than those without the condition.

Due to its potential role in the regulation of cholesterol levels, CFHR2 has been identified as a potential drug target for the treatment of CVD. Researchers are currently working to develop new drugs that target CFHR2 in order to treat individuals with FH and prevent the development of cardiovascular disease.

CFHR2 has also been identified as a potential biomarker for the diagnosis and monitoring of CVD. Studies have shown that individuals with FH have higher levels of CFHR2 in their blood than those without the condition. Additionally, the levels of CFHR2 have been shown to be a predictor of the risk of cardiovascular disease in individuals with FH.

The discovery of CFHR2 as a potential drug target and biomarker for CVD has the potential to revolutionize the field of cardiovascular medicine. By developing new treatments that target CFHR2, researchers hope to improve patient outcomes and reduce the burden of CVD on society.

In conclusion, CFHR2 is a gene that has been shown to play a significant role in the regulation of cholesterol levels and the development of FH. As a potential drug target and biomarker for CVD, CFHR2 has the potential to lead to new treatments for individuals with FH and improve patient outcomes. Further research is needed to fully understand the role of CFHR2 in the regulation of CVD and to develop effective treatments.

Protein Name: Complement Factor H Related 2

Functions: Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism

The "CFHR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFHR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets